Kommentar zu Therapieoptionen beim Seminom im klinischen Stadium II

• Literatur

• 1 Patel HD, Srivastava A, Alam R. et al. Radiotherapy for stage I and II testicular seminomas: Secondary malignancies and survival. Urol Oncol – Semin Orig Investig 2017; 35: 606.e1-606.e7
• 2 Giannatempo P, Greco T, Mariani L. et al. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. Ann Oncol 2015; 26: 657-668
• 3 Hellesnes R, Kvammen Ø, Myklebust TÅ. et al. Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era. Int J Cancer 2019; 147: 21-32
• 4 de Haas EC, Altena R, Boezen HM. et al. Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol 2013; 24: 749-575
• 5 Kero AE, Järvelä LS, Arola M. et al. Cardiovascular morbidity in long-term survivors of early-onset cancer: a population-based study. Int J Cancer 2014; 134: 664-673
• 6 Warszawski N, Schmücking M, Samtleben G. et al. Die Strahlentherapie der regionären Lymphknotenstationen bei der Behandlung des Seminoms im Vergleich zur retroperitonealen Lymphadenektomie. Strahlenther Oncol 1996; 172: 250-254